Merck & Co. had a promising CGRP-receptor antagonist under development but discovered in late-stage clinical-trial testing that some patients experienced liver enzyme changes. In July of last year, the company said it was discontinuing development of the compound, telcagepant, after looking at all its trial data. Germany's Boehringer Ingelheim GmbH was also working on a CGRP antagonist but canceled development. A spokesman declined to comment.
默克公司(Merck & Co.)曾经研制了一种让人看好的CGRP感受器官拮抗药,但是在后期的临床测试中发现,有些患者出现了肝脏 改变的情况。去年7月,该公司称,在查看了所有试验数据之后,公司不再继续研制这种名为telcagepant的化学药物。德国的勃林格殷格翰制药公司(Boehringer Ingelheim GmbH)也曾研制过一种CGRP拮抗药,但后来终止了该产品的开发。一名发言人拒绝置评。
Bristol-Myers Squibb Co. is conducting several early stage studies on CGRP antagonists and other companies are testing or may begin development of similar compounds as well.
百时美施贵宝公司(Bristol-Myers Squibb Co.)正在进行几种CGRP拮抗药的早期研究,其它公司也在对类似药物进行测试或者准备开始进行开发。
Researchers and companies also are trying to develop artificial antibodies that, when injected, would glom onto CGRP in the bloodstream or brain, before it reaches the receptors in the brain, or by blocking the receptors.
【难治的偏头痛让科学家头痛】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15